Job ID: 10100
Job Title: Phase I Oncology Leader
Location: Pittsburgh, PA
Phase I Oncology Leader
Division of Malignant Hematology and Medical Oncology
Department of Medicine
UPMC Hillman Cancer Center | Pittsburgh, PA
Early Phase Oncology Research Leader – Interested in Phase I and Cancer Therapeutics at a Comprehensive Cancer Center
Building upon a foundation of pioneering cancer research and international leadership in medical oncology and malignant hematology, the UPMC Hillman Cancer Center at the University of Pittsburgh is seeking an accomplished academic oncologist to join our faculty as the leader of our Phase I and Immunotherapy Drug Development Center (IDDC) to provide leadership and strategic direction, in collaboration with other members of the senior leadership team, for growth and expansion of a robust early phase translational research program. This individual will drive the scientific agenda forward, ushering in a new era of achievement and influence in the field of Cancer Research on an international scale.
The world-renowned UPMC Hillman Cancer Center, celebrating its 41st year as a leading center for cancer research, is one of 57 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers in the United States, one of three in Pennsylvania, and the only one in western Pennsylvania.
The Phase I & IDDC Leader plays a critical role in leading groundbreaking research within the established Cancer Therapeutics research program. The IDDC Leader will closely collaborate with other clinical, translational, and population scientists to enhance the Center’s reputation of extramural funding and commitment to cancer research collaborations across the UPMC Hillman Cancer Center at the University of Pittsburgh. The incumbent will have a primary appointment in the Department of Medicine at the University of Pittsburgh School of Medicine (UPSOM) and will be a member of UPMC Hillman Cancer Center. This position requires a dynamic, passionate, and experienced academic physician-scientist leader/investigator with extensive phase I experience and a proven track record of partnering with pharmaceutical companies to secure agents and funding for investigator initiated clinical trials as well as success in grant writing and producing high impact peer-reviewed publications.
Developments in cutting-edge clinical and translational research coupled with robust, collaborative research are the key ingredients to the continued growth and success of UPMC Hillman and the Division of Malignant Hematology and Medical Oncology in the Department of Medicine. This translational scientist will work closely with the UPMC Hillman Cancer Center Director and the Chief of the Division of Malignant Hematology/Medical Oncology to fully leverage the extensive scientific and technological resources available within UPMC and UPSOM.
CANDIDATE EXPECTATIONS
- Build on a solid Phase I program foundation.
- Serve as PI for active Phase I trials.
- Ability to manage and oversee 20-25 faculty and staff.
- Heavy collaboration with pharmaceutical industry.
- Collaborate with Phase I leads in each disease group.
- Ability to network with community physicians and build on the existing referral base.
- Experience with early phase trials of small molecule inhibitors, antibody-drug conjugates and immunotherapy.
KEY ATTRIBUTES OF PHASE I & IDDC LEADER, UPMC HILLMAN CANCER CENTER
Candidates for the position of the Phase I and Immunotherapy Drug Development Center (IDDC) Leader in the Division of Malignant Hematology/Medical Oncology and the UPMC Cancer Center will possess demonstrated track-record of leadership, excellent communication skills, and publications in high-impact journals.
The candidate should have a strong commitment to collaborating with other clinical, translational, and population scientists and have the necessary skills for grant writing and producing peer-reviewed publications. Successful candidates will have MD or MD, PhD or equivalent and relevant laboratory and leadership experience. Preferential consideration will be given to those from NCI designated cancer centers with scientific programs or other leadership experience. Eligible for medical licensure in the Commonwealth of Pennsylvania.
UPMC HILLMAN CANCER CENTER
Located in the city of Pittsburgh (routinely ranked as one of the top most livable and affordable U.S. cities), UPMC Hillman is an NCI-designated Comprehensive Cancer Center with over 300 members; five research programs in basic, translational, clinical, and population sciences; ten shared resources that receive funding from our NCI Cancer Center Support Grant https://hillmanresearch.upmc.edu/research/; and a 2024 institutional funding base of nearly $110 million. In 2024, the University of Pittsburgh School of Medicine ranked #8 in overall NIH funding. UPMC Hillman Cancer Center serves a catchment area of 29 Western Pennsylvania counties and provides unique opportunities to collaborate with clinical and translational research programs involved in cancer patient care.
APPLICATION INSTRUCTIONS
To ensure full consideration, inquiries, nominations, CVs and letters of interests should be submitted electronically in confidence to UPMC’s executive search partner, Mark Foutz: mfoutz@kbic.com and/or academicmedicine@kbic.com or call (972) 265-5369.
EEO/AA Employers.
